Showing results (61-70 of 79) with videos related to
Sort By:
Pageof 8
Clinical Therapeutics|February 11, 2014
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillationGregory Y H Lip, Thitima Kongnakorn, Hemant Phatak, et al.The Journal of Allergy and Clinical Immunology. in Practice|November 28, 2017
Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based AnalysisAaron M Drucker, Abrar A Qureshi, Caroline Amand, et al.Health Affairs (Project Hope)|October 11, 2012
The large social value resulting from use of statins warrants steps to improve adherence and broaden treatmentDavid C Grabowski, Darius N Lakdawalla, Dana P Goldman, et al.Pharmacoeconomics|December 18, 2009
Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the USVirginia M Rosen, Douglas C A Taylor, Hemangi Parekh, et al.Advances in Therapy|March 14, 2019
Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic DrugsErnest Choy, Nick Freemantle, Clare Proudfoot, et al.European Heart Journal|February 12, 2014
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillationPaul Dorian, Thitima Kongnakorn, Hemant Phatak, et al.Dermatology and Therapy|September 22, 2017
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in AdultsAndreas Kuznik, Gaëlle Bégo-Le-Bagousse, Laurent Eckert, et al.RMD Open|March 20, 2019
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analysesErnest Choy, Nick Freemantle, Clare Proudfoot, et al.Journal of Managed Care & Specialty Pharmacy|August 5, 2021
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinomaEleanor Paul, Gerasimos Konidaris, Shannon Cope, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2022
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50Andreas Kuznik, Caitlin Smare, Chieh-I Chen, et al.Pageof 8